Compare Credo Technology Group Holding Ltd (CRDO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Twist Bioscience Corp — how do they compare? Credo Technology Group Holding Ltd trades at $216.99 (market cap $39.82B), while Twist Bioscience Corp trades at $156.21 (market cap $10.08B). The key difference: Credo Technology Group Holding Ltd is far larger — about 4× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Twist Bioscience Corp for 27 Days on average.
| CRDO | TWST | |
|---|---|---|
Market Cap | $39.82B | $10.08B |
Volume | 9,451,558 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $302.52 | $205.00 |
52-Week Low | $87.81 | $25.45 |
Typical Hold Time | 22 Days | 27 Days |
Enterprise Value | $39.08B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $220.01, down 0.37% on the day, with strong technical momentum showing bullish moving averages and key support at $213. The company demonstrates exceptional fundamental strength with 114.7% YoY revenue growth and 33.83% net income margins, though valuation metrics remain elevated with a P/E of 74.6. Recent earnings beats and analyst optimism highlight CRDO's position in AI infrastructure connectivity.
Outlook remains positive given triple-digit revenue growth and expanding AI data center demand, but premium valuation and insider selling present near-term risks. Wall Street consensus targets $267.33 with 87.5% buy ratings, though execution risks and customer concentration require monitoring amid rapid expansion.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
